Considering the limitations of current anti-VEGF therapies, alternative antiangiogenic therapies that do not serve as direct inhibitors of VEGF-A may have potential benefits for the treatment of diabetic nephropathy. The gene discussed is VEGFA; the disease is diabetic kidney disease.